Details of the Drug Combination

General Information of Drug Combination (ID: DCEMJ9A)

Drug Combination Name
1-((2-chlorophenyl)diphenylmethyl)-1H-pyrazole Acetohydroxamic Acid
Indication
Disease Entry Status REF
Chronic myelogenous leukemia Investigative [1]
Component Drugs 1-((2-chlorophenyl)diphenylmethyl)-1H-pyrazole   DMQEJVU Acetohydroxamic Acid   DMYX7NI
Small molecular drug Small molecular drug
2D MOL 2D MOL
3D MOL 3D MOL
High-throughput Screening Result Testing Cell Line: KBM-7
Zero Interaction Potency (ZIP) Score: 5.56
Bliss Independence Score: 5.56
Loewe Additivity Score: 17.6
LHighest Single Agent (HSA) Score: 17.6

Molecular Interaction Atlas of This Drug Combination

Molecular Interaction Atlas (MIA)
Indication(s) of 1-((2-chlorophenyl)diphenylmethyl)-1H-pyrazole
Disease Entry ICD 11 Status REF
Conjunctival fibrosis 9A61.3 Investigative [2]
1-((2-chlorophenyl)diphenylmethyl)-1H-pyrazole Interacts with 2 DTT Molecule(s)
DTT Name DTT ID UniProt ID Mode of Action REF
Calcium-activated potassium channel (KCN) TTMNI76 NOUNIPROTAC Inhibitor [4]
Calcium-activated potassium channel KCa3.1 (KCNN4) TT7M9I6 KCNN4_HUMAN Blocker (channel blocker) [5]
------------------------------------------------------------------------------------
Indication(s) of Acetohydroxamic Acid
Disease Entry ICD 11 Status REF
Urinary tract infection GC08 Approved [3]
Acetohydroxamic Acid Interacts with 1 DTT Molecule(s)
DTT Name DTT ID UniProt ID Mode of Action REF
Bacterial Urease (Bact ureC) TTAS2UO URE1_KLEAE Inhibitor [6]
------------------------------------------------------------------------------------

References

1 CheMBL Affinity Phenotypic Cellular Interaction Assay ID: CHEMBL1125966
2 Blockade of KCa3.1: A novel target to treat TGF-1 induced conjunctival fibrosis.Exp Eye Res. 2018 Feb;167:140-144.
3 FDA Approved Drug Products from FDA Official Website. 2009. Application Number: (NDA) 018749.
4 Inhibitors of potassium channels KV1.3 and IK-1 as immunosuppressants. Bioorg Med Chem Lett. 2009 Apr 15;19(8):2299-304.
5 Blockade of the intermediate-conductance calcium-activated potassium channel as a new therapeutic strategy for restenosis. Circulation. 2003 Sep 2;108(9):1119-25.
6 Enzymatic, immunological and phylogenetic characterization of Brucella suis urease. BMC Microbiol. 2008 Jul 19;8:121.